Insmed (INSM)

• Market cap: $22B
• 1 day: -1.58%
• 5 days: -4.7%
• 1 month: -4.81%
• 3 months: -25.56%
• 6 months: -35.3%
• Year to date: -42.7%
• 1 year: -3.51%
• 5 years: 312.56%
• 10 years: 773.41%
• Sector: Healthcare
• Industry: Biotechnology

About: Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Employees: 1,664